In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Author
Sahu, AditiKose, Kivanc
Kraehenbuehl, Lukas
Byers, Candice
Holland, Aliya
Tembo, Teguru
Santella, Anthony
Alfonso, Anabel
Li, Madison
Cordova, Miguel
Gill, Melissa
Fox, Christi
Gonzalez, Salvador
Kumar, Piyush
Wang, Amber Weiching
Kurtansky, Nicholas
Chandrani, Pratik
Yin, Shen
Mehta, Paras
Navarrete-Dechent, Cristian
Peterson, Gary
King, Kimeil
Dusza, Stephen
Yang, Ning
Liu, Shuaitong
Phillips, William
Guitera, Pascale
Rossi, Anthony
Halpern, Allan
Deng, Liang
Pulitzer, Melissa
Marghoob, Ashfaq
Chen, Chih-Shan Jason
Merghoub, Taha
Rajadhyaksha, Milind
Journal title
Nature communicationsDate Published
2022-09-09Publication Volume
13Publication Issue
1Publication Begin page
5312
Metadata
Show full item recordAbstract
Response to immunotherapies can be variable and unpredictable. Pathology-based phenotyping of tumors into 'hot' and 'cold' is static, relying solely on T-cell infiltration in single-time single-site biopsies, resulting in suboptimal treatment response prediction. Dynamic vascular events (tumor angiogenesis, leukocyte trafficking) within tumor immune microenvironment (TiME) also influence anti-tumor immunity and treatment response. Here, we report dynamic cellular-level TiME phenotyping in vivo that combines inflammation profiles with vascular features through non-invasive reflectance confocal microscopic imaging. In skin cancer patients, we demonstrate three main TiME phenotypes that correlate with gene and protein expression, and response to toll-like receptor agonist immune-therapy. Notably, phenotypes with high inflammation associate with immunostimulatory signatures and those with high vasculature with angiogenic and endothelial anergy signatures. Moreover, phenotypes with high inflammation and low vasculature demonstrate the best treatment response. This non-invasive in vivo phenotyping approach integrating dynamic vasculature with inflammation serves as a reliable predictor of response to topical immune-therapy in patients.Citation
Sahu A, Kose K, Kraehenbuehl L, Byers C, Holland A, Tembo T, Santella A, Alfonso A, Li M, Cordova M, Gill M, Fox C, Gonzalez S, Kumar P, Wang AW, Kurtansky N, Chandrani P, Yin S, Mehta P, Navarrete-Dechent C, Peterson G, King K, Dusza S, Yang N, Liu S, Phillips W, Guitera P, Rossi A, Halpern A, Deng L, Pulitzer M, Marghoob A, Chen CJ, Merghoub T, Rajadhyaksha M. In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response. Nat Commun. 2022 Sep 9;13(1):5312. doi: 10.1038/s41467-022-32738-7. PMID: 36085288; PMCID: PMC9463451.DOI
10.1038/s41467-022-32738-7ae974a485f413a2113503eed53cd6c53
10.1038/s41467-022-32738-7
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Related articles
- Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
- Authors: Mullins SR, Vasilakos JP, Deschler K, Grigsby I, Gillis P, John J, Elder MJ, Swales J, Timosenko E, Cooper Z, Dovedi SJ, Leishman AJ, Luheshi N, Elvecrog J, Tilahun A, Goodwin R, Herbst R, Tomai MA, Wilkinson RW
- Issue date: 2019 Sep 11
- Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade.
- Authors: Zheng W, Qian C, Tang Y, Yang C, Zhou Y, Shen P, Chen W, Yu S, Wei Z, Wang A, Lu Y, Zhao Y
- Issue date: 2022
- Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
- Authors: Lee WS, Kim DS, Kim JH, Heo Y, Yang H, Go EJ, Kim JH, Lee SJ, Ahn BC, Yum JS, Chon HJ, Kim C
- Issue date: 2022 Jun
- Is there a role for Gallium-67 SPECT in distinguishing progression and pseudoprogresion in oncologic patients receiving immunotherapy?
- Authors: Mauri D, Tsiouris S, Gkoura S, Gazouli I, Ntellas P, Amylidis A, Kampletsas L, Fotopoulos A
- Issue date: 2021
- Cocktail strategy for 'cold' tumors therapy via active recruitment of CD8+ T cells and enhancing their function.
- Authors: Li X, Luo L, Jiang M, Zhu C, Shi Y, Zhang J, Qin B, Luo Z, Guo X, Lu Y, Shan X, Liu Y, Du Y, Ling P, You J
- Issue date: 2021 Jun 10